U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX17777252: GSM6613573: v-abl transformed B cells, Chk1i LY2603618, run2, rep1; Mus musculus; OTHER
4 ILLUMINA (NextSeq 550) runs: 7M spots, 525.6M bases, 174Mb downloads

External Id: GSM6613573_r1
Submitted by: Columbia University
Study: ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion [CRISPR-Cas9 gRNA screen]
show Abstracthide Abstract
The ATR kinase, which coordinates cellular responses to DNA replication stress, is also essential for the proliferation of normal unstressed cells. Although its role in the replication stress response is well defined, the mechanisms by which ATR supports normal cell proliferation remain elusive. Here, we show that Atr is dispensable for the viability of G0-arrested naïve B cells. However, upon cytokine-induced proliferation, Atr-deficient B cells initiate DNA replication efficiently in early S phase, but by mid-S phase they display dNTP depletion, fork stalling, and replication failure. Nonetheless, productive DNA replication can be restored in Atr-deficient cells by pathways that suppress origin firing, such as downregulation of CDC7 and CDK1 kinase activities. Together, these findings indicate that ATR supports the proliferation of normal unstressed cells by tempering the pace of origin firing during the early S phase to avoid exhaustion of dNTPs and other replication factors. Overall design: We set up a genome-wide CRISPR-Cas9 screen targeting 18,424 different genes with 4-5 gRNAs each in v-abl transformed wild-type mouse B cells treated with the IC90 dose of 1 of 2 ATR inhibitors (VE821 or AZD6738) or a Chk1 inhibitor (LY2603618), in triplicates, for 6 days and compared gRNA representation to DMSO-treated controls.
Sample: v-abl transformed B cells, Chk1i LY2603618, run2, rep1
SAMN31132264 • SRS15303505 • All experiments • All runs
Organism: Mus musculus
Library:
Name: GSM6613573
Instrument: NextSeq 550
Strategy: OTHER
Source: GENOMIC
Selection: other
Layout: SINGLE
Construction protocol: At least 30 million cells were collected in triplicate for each treatment before dox-induction, after dox-induction but before drug treatment, and after 6 days of drug treatment. Cells were lysed and genomic DNA was extracted. gRNA from extracted genomic DNA was amplified according to (Joung J, et al., Nat Protoc, 2017) using 2.5ug DNA x 96 reactions per treatment, NEBNext High Fidelity Master Mix (2x) (New England Biolabs) and NGS-Lib-Fwd and NGS-Lib-KO-Rev primers. PCR reactions were purified using Zymospin columns (Zymo Research) and cleaned up using AMPureXP beads (Beckman Coulter). Amplicon-seq of gRNAs harvested from cells.
Runs: 4 runs, 7M spots, 525.6M bases, 174Mb
Run# of Spots# of BasesSizePublished
SRR217827541,794,565134.7M45.6Mb2022-12-31
SRR217827551,770,877132.9M44.6Mb2022-12-31
SRR217827561,635,920122.8M39.6Mb2022-12-31
SRR217827571,802,563135.3M44.3Mb2022-12-31

ID:
24695824

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...